- The TransCon platform is designed to optimize the delivery of known drugs to target tissues.
- The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum of the parts figure based on the current pipeline assets.
- This $9.5 B market cap company has three endocrinology products for rare diseases and two earlier-stage oncology products.
- There are multiple upcoming catalysts but the oncology data is perhaps the most important in terms of demonstrating the breadth of the platform’s potential.
For further details see:
Ascendis Pharma: A Promising Platform And A Rich Valuation